MHRA enforcement and safety tracker
The MHRA published 23 items in the 90 days to 2026-10-06, of which 4 relate to weight-loss medicines or synthetic peptides, 2 concern enforcement against illegal or unlicensed supply, and 3 are formal Drug Safety Updates. This page restates what the regulator published and links to each gov.uk original. It is an independent reporting record, not advice.
Full MHRA record, last 90 days
Everything the MHRA published between 2026-07-06 and 2026-10-06, newest first. We list the full record rather than only selected parts, so every item can be audited directly against the official government register.
Detailed Case Dossiers: Peptides & GLP-1 Enforcement
In-depth analysis of high-impact regulatory interventions, laboratory raid reports, court orders, and cross-regulator warnings impacting the synthetic peptide sector.
Conditional Approval: Semaglutide (Wegovy) for Non-Cirrhotic MASH Liver Fibrosis
MHRA grants conditional marketing authorization for semaglutide to treat adult patients with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-advanced hepatic scarring.
National Warning: Public Advertising Prohibition on Licensed & Unlicensed GLP-1 and Peptides
MHRA, ASA and GPhC jointly caution commercial entities against promoting prescription-only or unlicensed research peptides directly to consumers.
First Oral Peptide Tablet Approved for UK Weight Management (Prescription Only)
MHRA clears oral formulation of GLP-1 receptor agonist under strict POM classification, reiterating ban on general public advertising.
Criminal Enforcement: Interception of 12,000 Unlicensed Doses Including Retatrutide & Peptides
Special Investigations Unit carried out arrests and recovered 12,000 doses of unlicensed synthetic peptides manufactured without GMP standards.
High Court ISP Block Order: Dynamic Web Filtering for Counterfeit Peptide Portals
High Court orders top UK internet providers to implement dynamic domain filtering against rogue illicit drug websites supplying unapproved peptide vials.
Drug Safety Alert: Falsified Tirzepatide Multidose Cartridges Intercepted
National alert identifying counterfeit batch lots with unverified sterility and non-standard peptide concentrations circulating in grey market supply chains.
Check it yourself: the official sources
Trustly Pharma is an independent analytical publication. Nothing here replaces the statutory authority of the MHRA, GPhC, or ASA. Direct official portals for independent verification are indexed below.
MHRA Products Portal
The Summary of Product Characteristics and Patient Information Leaflet for every medicine licensed in the UK. This is the authoritative document for what a medicine is licensed to do.
Drug Safety Update
The MHRA monthly bulletin of safety advice for prescribers and patients. Where new risks and product information changes are formally announced.
Report an unlicensed or illegally supplied medicine
The MHRA statutory reporting channel for unlicensed sellers supplying prescription products unlawfully, and for submitting intelligence regarding suspected counterfeit reagents.
CAP Code and ASA Rulings
The UK advertising rules, including the ban on advertising prescription-only medicines to the public, and the published rulings that show how they are applied.
WADA Prohibited List
The annually updated list of substances and methods banned in sport. Many research peptides sit under S0 or S2. UK Anti-Doping enforces it on tested athletes.
Human Medicines Regulations 2012
The legislation that defines what counts as a medicine in the UK, and what constitutes illegal supply. A product marketed with medicinal claims is regulated as a medicine regardless of how it is labelled.
Submit a Regulatory Reference or Notice
The editorial curation board continuously monitors statutory gazettes, MHRA Enforcement Group bulletins, and regulatory border notices. Academic institutions or regulatory researchers submitting verifiable public documentation may reach the editorial desk via the institutional contact desk.